If your pharmacy just told you Semglee is unavailable and can't say when it's coming back, you're not imagining a temporary shortage. Semglee is gone — permanently. It joins a small but growing list of insulin products, including Levemir, that manufacturers have pulled from the U.S. market in the past two years as the glargine and basal insulin landscape consolidates around fewer brands.
This guide walks through exactly what happened to Semglee, what's replacing it, and how to switch to a new product without missing a dose or overpaying. We'll compare Rezvoglar, Basaglar, unbranded generic glargine, and Lantus side by side on cost, coverage, and patient assistance eligibility, so you can have a specific, informed conversation with your prescriber instead of guessing.
Why Semglee Was Discontinued
Biocon Biologics, which developed Semglee (insulin glargine-yfgn) and distributed it in the U.S. through a partnership with Viatris (Mylan), made a business decision to exit the U.S. insulin glargine market. The company discontinued both the vial and prefilled pen formulations of Semglee effective December 31, 2025.
This wasn't a manufacturing failure, contamination issue, or FDA safety action. It was a commercial decision, similar to Novo Nordisk's 2024 discontinuation of Levemir. The U.S. long-acting insulin market has become intensely price-competitive since multiple interchangeable biosimilars entered, and not every manufacturer chose to keep competing at the margins that resulted.
This is a full, permanent discontinuation — not a temporary shortage. Semglee will not return to pharmacy shelves. Any remaining product in the supply chain is being sold through, but no new manufacturing is occurring.
Semglee Discontinuation Timeline
| Date | What Happened |
|---|---|
| Mid-to-late 2025 | Regional shortages of Semglee vials and pens intensify, especially in the Pacific Northwest and Northeast. |
| December 31, 2025 | Biocon Biologics formally discontinues Semglee vials and prefilled pens in the U.S. |
| January–March 2026 | Demand shifts to Lantus, Basaglar, Rezvoglar, and generic insulin glargine; insurance plans update formularies in real time. |
| May 4, 2026 | Langlara (insulin glargine-aldy), a newly FDA-approved interchangeable biosimilar, begins entering the market as an additional option. |
| Mid-2026 | Most major pharmacy chains report Semglee as fully removed from ordering systems; any remaining pharmacy stock is depleted. |
What Replaces Semglee
There is no single "official" successor to Semglee. Instead, patients and prescribers are choosing among several existing U-100 insulin glargine products, based on what a given insurance plan covers and what the patient can afford in cash. The four most common replacement paths are:
- Rezvoglar (insulin glargine-aglr) — Eli Lilly's FDA-interchangeable biosimilar to Lantus, available only as a prefilled KwikPen.
- Basaglar (insulin glargine) — Eli Lilly's earlier follow-on glargine product, also KwikPen only, generally with strong pharmacy availability.
- Generic (unbranded) insulin glargine — produced by manufacturers such as Winthrop, available in both vial and pen, usually the lowest cash price.
- Lantus (Sanofi) — the original brand-name reference product, available in vials and SoloStar pens, though sometimes at a higher list price than the alternatives above.
A newer fifth option: Langlara (insulin glargine-aldy), approved by the FDA on May 4, 2026, is a new interchangeable biosimilar entering the market. Availability is still expanding regionally as of August 2026, so ask your pharmacist whether it's stocked locally before counting on it.
Rezvoglar vs. Semglee: Are They the Same?
Rezvoglar and Semglee are both FDA-designated interchangeable biosimilars to Lantus — meaning both went through the FDA's interchangeability pathway and both deliver insulin glargine at U-100 strength. That's where the similarity in status ends.
- Manufacturer: Semglee was made by Biocon Biologics; Rezvoglar is made by Eli Lilly.
- Formulations: Semglee came in both a vial and a pen; Rezvoglar is KwikPen only — there is no Rezvoglar vial.
- Interchangeability target: Both were interchangeable with Lantus specifically, not with each other. A pharmacist could not (and still cannot) automatically substitute Rezvoglar for a Semglee prescription without a new script.
- Patient assistance: Rezvoglar is not currently part of the Lilly Cares Foundation formulary, which matters if you were relying on free medication through a manufacturer program.
If you need insulin in a vial (for a pump, syringe use, or personal preference), Rezvoglar won't work — it's pen-only. Basaglar is also pen-only. Generic insulin glargine or Lantus are your vial options.
Glargine Product Comparison Table
| Product | Manufacturer | Formulations | Interchangeable Status | Availability |
|---|---|---|---|---|
| Semglee | Biocon Biologics | Vial & pen | Was interchangeable with Lantus | Discontinued 12/31/2025 |
| Rezvoglar | Eli Lilly | KwikPen only | Interchangeable with Lantus | Available, growing supply |
| Basaglar | Eli Lilly | KwikPen only | Follow-on, not interchangeable designation | Widely available |
| Generic Insulin Glargine | Winthrop & others | Vial & pen | Interchangeable with Lantus (varies by maker) | Available, regional variation |
| Lantus | Sanofi | Vial & SoloStar pen | Reference product | Available; intermittent local stock-outs |
| Langlara | Manufacturer varies | Pen (expanding) | Interchangeable with Lantus | Newly launched, limited regions |
Cost Comparison
Cash prices for insulin glargine vary by pharmacy and by discount program, but the general order from cheapest to most expensive has held steady through 2026:
| Product | Typical Cash Price | Lowest-Cost Path |
|---|---|---|
| Generic Insulin Glargine | Lowest of the group | Discount card at a participating pharmacy |
| Basaglar | Low, capped for eligible patients | Eli Lilly $35/month Insulin Value Program |
| Rezvoglar | Similar to former Semglee pen pricing | Eli Lilly $35/month Insulin Value Program |
| Lantus | Higher list price | Sanofi Valyou Savings Program |
| Toujeo (U-300, not 1:1) | Comparable to Lantus | Sanofi Valyou Savings Program |
The $35/month insulin cap: Eli Lilly's Insulin Value Program caps out-of-pocket cost at $35/month for eligible patients on Basaglar, Humalog, and other Lilly insulins, including Rezvoglar in many cases. Check our insulin savings programs guide for how to enroll and which products qualify.
Before switching, run your specific medication and pharmacy through a drug price checker to compare real-time cash and discount prices at pharmacies near you — list prices and program caps only tell part of the story.
Coverage & Eligibility Comparison
Insurance formularies are still catching up to the Semglee discontinuation. Many commercial and Medicare Part D plans had Semglee listed as a preferred or exclusive glargine option — those plans have had to update their tiers throughout 2026.
| Insurance Situation | What to Expect |
|---|---|
| Commercial insurance, Semglee was preferred | Plan has likely re-mapped preferred status to Rezvoglar, Basaglar, or generic glargine — check your updated formulary. |
| Medicare Part D | Formulary tiers vary by plan; some plans require prior authorization for brand Lantus if a biosimilar is preferred. See our Medicare Part D guide. |
| Uninsured / cash-pay | Generic insulin glargine is usually cheapest; compare against manufacturer cash-pay programs like NovoCare Pharmacy or LillyDirect. |
| Underinsured (high deductible) | Manufacturer savings cards (Lilly, Sanofi) reduce cost regardless of Semglee's exit — see our manufacturer savings card guide. |
If your plan requires prior authorization for your new glargine product, don't wait until you're out of insulin to find out. Ask your prescriber's office to check now, and see our prior authorization guide for how the process generally works across GLP-1 and insulin products.
Patient Assistance Program Comparison
If you were receiving Semglee at no cost through a patient assistance program, that specific enrollment ends with the discontinuation. Here's how the two major manufacturer charity programs handle glargine replacements as of 2026.
| Program | Rezvoglar Covered? | Other Glargine/Insulin Covered | Income Limit |
|---|---|---|---|
| Lilly Cares Foundation PAP | Not on 2026 formulary | Humalog, Lyumjev, Basaglar, Humulin | ≤400% FPL (Group 2), uninsured or Medicare Part D |
| NeedyMeds discount & PAP directory | Search directly for current listings | Multiple manufacturer and state programs | Varies by program |
| BenefitsCheckUp (NCOA) | Not a PAP itself | Screens for state and federal programs, including Extra Help | Varies by program matched |
Important: Even though Eli Lilly manufactures Rezvoglar, it is not included in the Lilly Cares Foundation Patient Assistance Program formulary as of 2026. If you need free insulin through Lilly Cares, ask your prescriber about switching to Basaglar or Humalog instead, both of which remain PAP-eligible at the Group 2 (400% FPL) income tier.
For a full breakdown of income tiers, required documents, and how to apply, see our complete Eli Lilly Patient Assistance Program guide and our general Patient Assistance Programs overview.
Decision Tree: Which Glargine Should You Switch To?
Step 1: Do you need a vial (for a pump, syringe draws, or personal preference)?
✔ Yes → Choose generic insulin glargine or Lantus. Rezvoglar and Basaglar are pen-only.
✖ No → Continue to Step 2.
Step 2: Are you enrolled in (or hoping to enroll in) the Lilly Cares Patient Assistance Program for free insulin?
✔ Yes → Ask about Basaglar or Humalog, which are PAP-eligible. Rezvoglar is not currently covered by Lilly Cares.
✖ No → Continue to Step 3.
Step 3: Does your insurance plan list a specific preferred glargine product on its 2026 formulary?
✔ Yes → Ask your prescriber to write for that specific product to avoid a prior authorization delay.
✖ No / Uninsured → Compare cash prices for generic glargine, Basaglar, and Rezvoglar using a drug price checker, and apply any manufacturer $35/month cap you qualify for.
How to Switch, Step by Step
Check your current supply
Count how many days of Semglee you have left. If it's under two weeks, treat this as time-sensitive and call your prescriber's office directly rather than waiting for a routine refill request to bounce.
Contact your prescriber for a new prescription
Semglee's interchangeable status does not transfer to Rezvoglar, Basaglar, or generic glargine. Your pharmacist cannot make this substitution on their own — you need a new, separate prescription written for the replacement product.
Confirm coverage before you fill it
Call your insurance plan or check your online member portal to see which glargine products are preferred on your 2026 formulary. This can save you a rejected claim at the pharmacy counter.
Ask your pharmacist about vial vs. pen
If you were using a Semglee vial, make sure the new prescription is also for a vial if that's what you need — Rezvoglar and Basaglar don't offer one.
Apply any relevant savings program
If you're paying cash or facing a high deductible, enroll in the manufacturer's savings program for your new product (Lilly's Insulin Value Program or Sanofi's Valyou Savings Program) before your first fill.
Confirm your first dose with your care team
Even though the switch is typically 1:1 in units for U-100 products, confirm your exact dose and injection technique with your prescriber or a diabetes educator before your first injection of the new product.
Dose Conversion: What Changes and What Doesn't
| Switching To | Concentration | Dose Conversion |
|---|---|---|
| Rezvoglar | U-100 | Typically unit-for-unit |
| Basaglar | U-100 | Typically unit-for-unit |
| Generic Insulin Glargine | U-100 | Typically unit-for-unit |
| Lantus | U-100 | Typically unit-for-unit |
| Toujeo | U-300 (3x concentration) | NOT 1:1 — requires prescriber-guided dose review |
Never assume a dose conversion on your own. Even for unit-for-unit U-100 switches, confirm with your prescriber, especially if you also have kidney or liver changes, a new diet, or altered activity levels since your last dose review.
Pros and Cons of Each Option
Rezvoglar
- Interchangeable biosimilar status with Lantus, so pharmacists can substitute for Lantus prescriptions without a new script
- Growing pharmacy availability nationwide
- Eligible for Lilly's $35/month savings cap for many patients
- Pen only — no vial option
- Not on the Lilly Cares Patient Assistance Program formulary
Basaglar
- Long track record and broad insurance coverage
- Included in the Lilly Cares Patient Assistance Program at the Group 2 (400% FPL) tier
- Eligible for Lilly's $35/month savings cap
- Pen only — no vial option
- Not FDA-designated as interchangeable with Lantus (requires a prescription, not a pharmacy substitution)
Generic Insulin Glargine
- Usually the lowest cash price of the group
- Available in both vial and pen
- Regional supply can vary by manufacturer and pharmacy
- Not tied to a single manufacturer savings program
Lantus
- The original reference product with the longest safety track record
- Available in vial and SoloStar pen
- Sanofi's Valyou Savings Program can bring cash cost down significantly
- Higher list price than biosimilar alternatives
- Some regional pharmacy stock-outs reported in high-demand areas
Approval and Coverage Timelines
| Step | Typical Timeframe |
|---|---|
| New prescription sent electronically to pharmacy | Same day, if prescriber's office responds promptly |
| Insurance formulary check | Minutes to same day via your plan's online portal |
| Prior authorization, if required | 2–5 business days typically; can extend to 2 weeks with appeals |
| Manufacturer savings card enrollment | Immediate to same-day for most online enrollments |
| Lilly Cares Patient Assistance Program (Basaglar/Humalog only) | 1–3 weeks for a complete application |
Renewing Coverage After You Switch
Once you've moved to a new glargine product, treat it like any other ongoing prescription — but keep a few Semglee-specific details in mind during your next renewal cycle:
- Make sure your pharmacy profile no longer shows an active Semglee prescription that could cause confusion at refill time.
- If you enrolled in a manufacturer savings card for your new product, check its expiration date — most run through the end of the calendar year and require re-enrollment in January.
- If you're on a patient assistance program for Basaglar or Humalog, remember enrollment is typically for 12 months (or through year-end for Medicare Part D patients), after which you'll need to reapply with updated income documentation.
- If your insurance plan updates its formulary again next year, confirm your product is still preferred before your annual open enrollment ends.
Common Mistakes When Switching
- □ Assuming the pharmacist can automatically substitute Rezvoglar or Basaglar for an old Semglee prescription — a new script is required.
- □ Requesting a vial when the new prescription is for Rezvoglar or Basaglar, which are pen-only.
- □ Waiting until you're completely out of insulin before contacting your prescriber.
- □ Assuming Rezvoglar is covered by the Lilly Cares Patient Assistance Program — it currently is not.
- □ Confusing Toujeo (U-300) with a standard U-100 glargine — the dose is not interchangeable 1:1.
- □ Not checking your insurance formulary before filling, resulting in a rejected claim at the counter.
Most of these mistakes are avoidable with one phone call — either to your prescriber's office or your insurance plan — before you show up at the pharmacy.
Real Patient Examples
Example 1 — Commercially insured, was on Semglee pens: A patient whose commercial plan previously preferred Semglee found that the plan's 2026 formulary now lists Rezvoglar as the preferred pen. The prescriber sent a new script, the pharmacy filled it the same day, and the patient's copay stayed roughly the same.
Example 2 — Uninsured, was on a Semglee vial: Because Rezvoglar and Basaglar don't offer a vial, this patient switched to generic insulin glargine instead, using a pharmacy discount card to keep the cash price close to what they were paying for Semglee.
Example 3 — Enrolled in Lilly Cares for free insulin: A patient assumed Rezvoglar would be covered under their existing Lilly Cares enrollment since it's a Lilly product. It wasn't. Their prescriber switched them to Basaglar, which is on the 2026 Lilly Cares formulary, and enrollment continued without a gap.
Bottom Line
Semglee's discontinuation on December 31, 2025 was a manufacturer business decision, not a safety issue, but it still leaves patients needing to actively manage their own transition. There's no automatic pharmacy substitute — you need a new prescription, and the right replacement depends on whether you need a vial, whether you're relying on a patient assistance program, and what your specific insurance plan currently prefers.
Rezvoglar and Basaglar are the most common Lilly-made replacements, generic glargine is usually cheapest in cash, and Lantus remains available as the original reference product. Whichever you choose, confirm coverage and enroll in any applicable savings program before your first fill.
Frequently Asked Questions
Yes. Biocon Biologics, which markets Semglee in partnership with Viatris, discontinued both Semglee vials and Semglee prefilled pens effective December 31, 2025. Pharmacies are no longer able to order or dispense Semglee, and any remaining stock in the supply chain is being sold through. Patients who were taking Semglee need a new prescription for a replacement long-acting insulin.
There is no single one-to-one replacement. Instead, patients are moving to one of several U-100 insulin glargine products: Rezvoglar (Eli Lilly's interchangeable biosimilar), Basaglar (Eli Lilly's follow-on glargine), unbranded generic insulin glargine (from manufacturers such as Winthrop), or brand-name Lantus. Your prescriber and pharmacist will typically recommend the option with the best coverage under your specific insurance plan.
Not exactly, but they are comparable. Both are FDA-designated interchangeable biosimilars to Lantus, meaning both were reviewed against the same reference product and both deliver insulin glargine at U-100 concentration. Rezvoglar is manufactured by Eli Lilly and comes only in a prefilled KwikPen; Semglee was manufactured by Biocon and came in both a vial and a pen. The clinical effect is the same active ingredient at the same strength.
Yes. Semglee's interchangeable status only applied to substitutions between Semglee and Lantus at the pharmacy counter. Rezvoglar is a separate interchangeable biosimilar to Lantus, not to Semglee, so moving from Semglee to Rezvoglar, Basaglar, or generic glargine requires a new prescription from your provider rather than an automatic pharmacy-level swap.
For any U-100 insulin glargine product — Rezvoglar, Basaglar, Lantus, or generic glargine — the switch is typically unit-for-unit with no dose adjustment needed, since they share the same concentration. The exception is Toujeo, which is U-300 (three times as concentrated) and is not a 1:1 unit switch. Always confirm the concentration and dose with your prescriber before your first injection of a new product.
Unbranded (generic) insulin glargine is a separate biosimilar product line, not a relabeled version of Semglee. It contains the same active ingredient, insulin glargine, at the same U-100 concentration, and several manufacturers, including Winthrop, produce unbranded glargine pens and vials. It is often the lowest-cost cash-pay option and is commonly available through discount cards.
As of 2026, Rezvoglar is not included in the Lilly Cares Foundation Patient Assistance Program formulary, even though it is manufactured by Eli Lilly. Patients who need insulin at no cost through Lilly Cares should ask about Humalog, Lyumjev, Basaglar, or Humulin instead, which remain on the Lilly Cares formulary at the Group 2 (400% FPL) income tier.
Cash prices for Rezvoglar KwikPens typically run in a similar range to what Semglee pens cost before discontinuation, generally lower than brand Lantus. Eli Lilly's $35 insulin savings program can apply to Rezvoglar and Basaglar for eligible patients, and manufacturer coupons or pharmacy discount cards can bring the out-of-pocket cost down further for cash-paying patients.
Contact your prescriber as soon as possible. Because Semglee can no longer be filled, an active Semglee prescription sitting in your pharmacy's system will simply fail at refill time, which can cause a gap in your insulin supply. Ask your provider to send a new prescription for Rezvoglar, Basaglar, generic glargine, or Lantus before you run out of your current supply.
How We Researched This Guide
References
- U.S. Food & Drug Administration. Biosimilar and Interchangeable Biologics Guidance.
- Lilly Cares Foundation. Patient Assistance Program Formulary and Application.
- Eli Lilly and Company. Rezvoglar and Basaglar Product Information.
- Novo Nordisk. NovoCare Patient Support Overview.
- Medicare.gov. Medicare Part D Prescription Drug Coverage.
- Centers for Medicare & Medicaid Services. Part D Formulary Guidance.
- NeedyMeds. Patient Assistance and Discount Program Directory.
- National Council on Aging. BenefitsCheckUp.
Related Resources
Related Insulin & Patient Assistance Guides
- Eli Lilly Patient Assistance Program (Complete 2026 Guide)
- Patient Assistance Programs Overview
- Insulin Savings Programs Compared
- Manufacturer Savings Cards Explained
- Medicare Part D Coverage Guide
- Extra Help (LIS) Eligibility Guide
- GoodRx vs. Inside Rx: Which Saves More?
- Drug Price Checker Tool
- Prior Authorization Requirements Guide
Editorial Policy: Refill Relay content is researched using publicly available manufacturer discontinuation notices, FDA biosimilar designations, and standard patient assistance program materials. Every article is reviewed for clarity, accuracy and usefulness before publication.